Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.

[1]  F. Hirsch,et al.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Czirók,et al.  Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo , 2018, Clinical Cancer Research.

[3]  S. Albelda,et al.  Novel therapies for malignant pleural mesothelioma. , 2018, The Lancet. Oncology.

[4]  G. Reid,et al.  A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma , 2017, Molecular oncology.

[5]  Bingya Liu,et al.  Cancer‐associated fibroblast‐derived Lumican promotes gastric cancer progression via the integrin β1‐FAK signaling pathway , 2017, International journal of cancer.

[6]  U. Schumacher,et al.  Novel biomarkers in cancer: The whole is greater than the sum of its parts. , 2017, Seminars in cancer biology.

[7]  M. Krstic-Demonacos,et al.  Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma , 2017, Expert opinion on investigational drugs.

[8]  J. Vaquero,et al.  Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance , 2017, Oncogene.

[9]  Y. Sekido,et al.  E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells , 2017, Oncogene.

[10]  Shu Liu,et al.  Targeting YAP in malignant pleural mesothelioma , 2017, Journal of cellular and molecular medicine.

[11]  T. Nakano,et al.  Trametinib plus 4‐Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD‐1 and PD‐L1 in Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  D. Carey,et al.  Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells , 2017, Oncotarget.

[13]  J. Zucman‐Rossi,et al.  Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma , 2016, Clinical Cancer Research.

[14]  G. Scagliotti,et al.  Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines , 2016, Oncotarget.

[15]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[16]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[17]  Marie-Claude Jean.  Biomolecular Pathways and Malignant Pleural Mesothelioma , 2016 .

[18]  J. Bergh,et al.  The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer , 2015, Journal of internal medicine.

[19]  S. Vacher,et al.  ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels , 2015, British Journal of Cancer.

[20]  H. Pass,et al.  Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. , 2015, Methods in molecular biology.

[21]  M. Sayan,et al.  Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas. , 2014, American journal of respiratory cell and molecular biology.

[22]  B. Ghanim,et al.  Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. , 2014, American journal of respiratory and critical care medicine.

[23]  F. Galateau-Sallé,et al.  Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma , 2014, Oncogene.

[24]  A. Warth,et al.  Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma , 2014, Molecular Cancer Research.

[25]  Andrea I. McClatchey,et al.  Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship , 2014, Science Translational Medicine.

[26]  F. Galateau-Sallé,et al.  Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition , 2014, Clinical Cancer Research.

[27]  F. Galateau-Sallé,et al.  Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. , 2013, Mutagenesis.

[28]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[29]  Y. Kondo,et al.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes , 2012, Oncogene.

[30]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[31]  F. Galateau-Sallé,et al.  Molecular changes in mesothelioma with an impact on prognosis and treatment. , 2012, Archives of pathology & laboratory medicine.

[32]  A. Üren,et al.  Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells , 2012, Oncogene.

[33]  E. Giovannetti,et al.  Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin , 2011, British Journal of Cancer.

[34]  M. Jaurand,et al.  Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases , 2011, Journal of toxicology and environmental health. Part B, Critical reviews.

[35]  F. Galateau-Sallé,et al.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. , 2011, The American journal of pathology.

[36]  J. Heino,et al.  Lumican inhibits cell migration through α2β1 integrin. , 2010, Experimental cell research.

[37]  J. Testa,et al.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. , 2010, Genes & cancer.

[38]  Juswinder Singh,et al.  A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection , 2007 .

[39]  R Birngruber,et al.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. , 1999, Archives of ophthalmology.

[40]  Y. Miyata,et al.  Molecular cloning and characterization of a novel member of the MAP kinase superfamily , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[41]  M. Jaurand,et al.  in vitro effects of recombinant human interferon gamma on human mesothelioma cell lines , 1993, International journal of cancer.